ST. LOUIS -- The scientist who discovered “Sly Syndrome” nearly four decades ago and a team of colleagues at Saint Louis University are a step closer to finding an approach to treat the rare genetic ...

ST. LOUIS -- Findings by a Saint Louis University research team led by the scientist who discovered Sly Syndrome 32 years ago point to a new direction for research into the rare genetic disorder that ...

Ultragenyx Pharmaceuticals (RARE +3.9%) announces the dosing of the first patient in a Phase 2 clinical trial assessing Fast Track-designated recombinant human beta-glucuronidase (rhGUS) (UX003) for ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. When a disease affects only one in 200,000 Americans finding research money and attracting the interest of a pharmaceutical ...

Ultragenyx Pharmaceutical Inc. enrolled only 12 patients in the pivotal phase III study of its recombinant human beta-glucuronidase (rhGUS) candidate, also known as UX003, to treat ultra-rare ...

NEW YORK (AP) — Shares of Ultragenyx have more than doubled in their trading debut after the drug developer’s initial public offering raised $121 million. The Novato, Calif., company is developing ...

Ultragenyx Pharmaceutical Inc. RARE is seeing a steady uptake of its portfolio of marketed drugs that are approved for the treatment of rare and ultra-rare diseases. The company currently markets ...

Ultragenyx Pharmaceuticals' shares are trading 60% higher after pricing a secondary offering, reflecting optimism about its pipeline of rare disease treatments. The company has four commercial ...